Driving Innovation with MyD88-Targeted Pipelines
Our pipelines focus on critical pathways in MyD88-targeted therapies. We offer them for technology transfer and strategic partnerships, fostering collaboration to accelerate drug development.
-
Innovative Solutions
-
Advanced Technologies
-
Streamlined Processes
-
Efficient Development
-
Collaborative Innovation
-
Cutting-Edge Research
MyD88 Focus
Designed with a strong focus on MyD88-targeted therapies, our pipeline addresses key pathways to drive therapeutic innovation and is open for technology transfer or strategic partnerships.
TLR/MyD88 Inhibitor for Psoriasis
Focused on targeting key pathways in psoriasis, this inhibitor offers a novel approach to managing inflammation.
IRI Emergency IV Therapy
Designed for ischemia-reperfusion injury in acute myocardial infarction, this IV therapy minimizes tissue damage.
Oral Tablets for Colitis & Colorectal Cancer
This oral formulation addresses inflammatory and oncological pathways in colitis and colorectal cancer.
Metabolic Disorders Oral Tablets
This product targets metabolic pathways, offering solutions for diabetes, obesity, and fatty liver disease.
SLE Oral Therapy
This oral therapy is tailored to modulate autoimmune pathways in systemic lupus erythematosus.
Transplant Rejection Therapy (Oral/IV)
This therapy supports immune modulation in organ transplant settings, available in oral and IV forms.